A NEW TREATMENT FOE ANAEMIA WILL SOON BE AVAILABLE IN EGYPT
Astellas Egypt, a subsidiary of Astellas Pharma Inc., will soon launch a new treatment for anaemia associated with Chronic Kidney Disease (CKD).
The treatment is described as a cost-effective approach for adults diagnosed with CKD, which ranks amongst the top five causes of death across Egypt. CKD is characterised by a gradual loss of kidney function that can ultimately result in kidney failure or end-stage kidney disease, necessitating dialysis or a kidney transplant.
